Who Will Benefit from Charged-Particle Therapy?

Charged-particle therapy (CPT) such as proton beam therapy (PBT) and carbon-ion radiotherapy (CIRT) exhibit substantial physical and biological advantages compared to conventional photon radiotherapy. As it can reduce the amount of radiation irradiated in the normal organ, CPT has been mainly applie...

Full description

Saved in:
Bibliographic Details
Published inCancer research and treatment Vol. 53; no. 3; pp. 621 - 634
Main Authors Kim, Kyung Su, Wu, Hong-Gyun
Format Journal Article
LanguageEnglish
Published Korea (South) Korean Cancer Association 01.07.2021
대한암학회
Subjects
Cost-Benefit Analysis
Heavy Ion Radiotherapy - adverse effects
Heavy Ion Radiotherapy - economics
Heavy Ion Radiotherapy - methods
Humans
Incidence
Neoplasms - radiotherapy
Organs at Risk - radiation effects
Patient Selection
Photons - adverse effects
Radiation Injuries - epidemiology
Radiation Injuries - etiology
Special
Treatment Outcome
의학일반
Carbon-ion radiotherapy
Charged-particle therapy
Proton beam therapy
Online AccessGet full text
ISSN1598-2998
2005-9256
2005-9256
DOI10.4143/crt.2021.299

Cover

Abstract Charged-particle therapy (CPT) such as proton beam therapy (PBT) and carbon-ion radiotherapy (CIRT) exhibit substantial physical and biological advantages compared to conventional photon radiotherapy. As it can reduce the amount of radiation irradiated in the normal organ, CPT has been mainly applied to pediatric cancer and radioresistent tumors in the eloquent area. Although there is a possibility of greater benefits, high set-up cost and dearth of high level of clinical evidence hinder wide applications of CPT. This review aims to present recent clinical results of PBT and CIRT in selected diseases focusing on possible indications of CPT. We also discussed how clinical studies are conducted to increase the number of patients who can benefit from CPT despite its high cost.
AbstractList Charged-particle therapy (CPT) such as proton beam therapy (PBT) and carbon-ion radiotherapy (CIRT) exhibit substantial physical and biological advantages compared to conventional photon radiotherapy. As it can reduce the amount of radiation irradiated in the normal organ, CPT has been mainly applied to pediatric cancer and radioresistent tumors in the eloquent area. Although there is a possibility of greater benefits, high set-up cost and dearth of high level of clinical evidence hinder wide applications of CPT. This review aims to present recent clinical results of PBT and CIRT in selected diseases focusing on possible indications of CPT. We also discussed how clinical studies are conducted to increase the number of patients who can benefit from CPT despite its high cost. KCI Citation Count: 1
Charged-particle therapy (CPT) such as proton beam therapy (PBT) and carbon-ion radiotherapy (CIRT) exhibit substantial physical and biological advantages compared to conventional photon radiotherapy. As it can reduce the amount of radiation irradiated in the normal organ, CPT has been mainly applied to pediatric cancer and radioresistent tumors in the eloquent area. Although there is a possibility of greater benefits, high set-up cost and dearth of high level of clinical evidence hinder wide applications of CPT. This review aims to present recent clinical results of PBT and CIRT in selected diseases focusing on possible indications of CPT. We also discussed how clinical studies are conducted to increase the number of patients who can benefit from CPT despite its high cost.
Charged-particle therapy (CPT) such as proton beam therapy (PBT) and carbon-ion radiotherapy (CIRT) exhibit substantial physical and biological advantages compared to conventional photon radiotherapy. As it can reduce the amount of radiation irradiated in the normal organ, CPT has been mainly applied to pediatric cancer and radioresistent tumors in the eloquent area. Although there is a possibility of greater benefits, high set-up cost and dearth of high level of clinical evidence hinder wide applications of CPT. This review aims to present recent clinical results of PBT and CIRT in selected diseases focusing on possible indications of CPT. We also discussed how clinical studies are conducted to increase the number of patients who can benefit from CPT despite its high cost.Charged-particle therapy (CPT) such as proton beam therapy (PBT) and carbon-ion radiotherapy (CIRT) exhibit substantial physical and biological advantages compared to conventional photon radiotherapy. As it can reduce the amount of radiation irradiated in the normal organ, CPT has been mainly applied to pediatric cancer and radioresistent tumors in the eloquent area. Although there is a possibility of greater benefits, high set-up cost and dearth of high level of clinical evidence hinder wide applications of CPT. This review aims to present recent clinical results of PBT and CIRT in selected diseases focusing on possible indications of CPT. We also discussed how clinical studies are conducted to increase the number of patients who can benefit from CPT despite its high cost.
Author Wu, Hong-Gyun
Kim, Kyung Su
AuthorAffiliation 5 Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea
2 Department of Radiation Oncology, Seoul National University Hospital, Seoul, Korea
1 Department of Radiation Oncology, Ewha Womans University College of Medicine, Seoul, Korea
4 Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
3 Institute of Radiation Medicine, Seoul National University Medical Research Center, Seoul, Korea
AuthorAffiliation_xml – name: 4 Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
– name: 3 Institute of Radiation Medicine, Seoul National University Medical Research Center, Seoul, Korea
– name: 5 Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea
– name: 1 Department of Radiation Oncology, Ewha Womans University College of Medicine, Seoul, Korea
– name: 2 Department of Radiation Oncology, Seoul National University Hospital, Seoul, Korea
Author_xml – sequence: 1
  givenname: Kyung Su
  surname: Kim
  fullname: Kim, Kyung Su
– sequence: 2
  givenname: Hong-Gyun
  surname: Wu
  fullname: Wu, Hong-Gyun
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34176253$$D View this record in MEDLINE/PubMed
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002738402$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNptkV1PwjAYhRuDkQ-989rsUhMHbdd2640GiR8kJBqD4bIpXQeVsWI3TPj3doBEjVcnaZ_3nLc9bdAobKEBOEewSxCJespVXQwx6mLOj0ALQ0hDjilrgBaiPAn9cdIE7bJ8h5CRKEYnoBkRFDNMoxboTeY2mJg8D-50oTNTBZmzy2Awl26m0_BFusqoXAfjuXZytbk9BceZzEt9ttcOeHu4Hw-ewtHz43DQH4UqIkkVRjpWkk1TzJI0y2hKFJQ6klBKHUvGKUaMY68M4VhlJPY8YVT57dJUpTCOOuBq51u4TCyUEVaarc6sWDjRfx0PBU_8cwj37M2OXa2nS50qXVRO5mLlzFK6zXby901h5t7nUySYI-RNOuByb-Dsx1qXlViaUuk8l4W261JgSijniCV11sXPrEPI94964HoHKGfL0unsgCAo6sKEL0zUhQnfjMfxH1yZSlbG1pua_P-hL1UPmBk
CitedBy_id crossref_primary_10_1186_s12885_024_13231_4
crossref_primary_10_1186_s13014_023_02264_x
crossref_primary_10_1016_j_canlet_2023_216268
crossref_primary_10_1088_1361_6560_aca387
crossref_primary_10_1093_jrr_rrae086
crossref_primary_10_1016_j_cytogfr_2023_11_003
crossref_primary_10_4143_crt_2021_707
Cites_doi 10.1016/j.radonc.2014.08.017
10.1002/cam4.1350
10.1007/s00066-009-2020-x
10.1186/s13014-016-0637-3
10.1186/1748-717x-9-26
10.1200/jco.19.02274
10.37765/ajmc.2020.42398
10.1111/hepr.12874
10.1080/02841860500326257
10.1016/j.ijrobp.2006.09.022
10.1016/j.ijrobp.2013.05.002
10.1186/s12885-019-6108-0
10.1016/j.ijrobp.2015.11.004
10.1016/j.radonc.2016.12.014
10.1159/000486997
10.1016/j.ijrobp.2013.11.007
10.1016/j.radonc.2017.05.007
10.1016/s1470-2045(14)71207-0
10.21873/invivo.11944
10.1016/j.adro.2019.09.007
10.3857/roj.2019.00633
10.1259/bjr.20160790
10.1001/archotol.132.11.1242
10.1016/j.radonc.2016.10.009
10.1016/j.radonc.2017.12.017
10.1002/cam4.1830
10.1016/j.ijrobp.2008.12.019
10.4143/crt.2017.096
10.1002/cam4.1679
10.1016/j.ijrobp.2016.02.038
10.1056/nejmoa1209825
10.3390/cancers9060066
10.1186/s13014-019-1347-4
10.1016/j.radonc.2015.05.010
10.1016/j.ijrobp.2016.02.031
10.1093/jrr/rru034
10.1002/jso.22127
10.1186/s13014-020-01653-w
10.1111/cas.13890
10.3390/cancers13010112
10.1016/j.radonc.2019.04.027
10.1016/j.radonc.2018.08.026
10.1259/bjr.20200183
10.1158/1078-0432.ccr-04-1350
10.1016/j.ijrobp.2012.01.072
10.1007/s00066-014-0604-6
10.1097/brs.0b013e318296e7d7
10.1097/jto.0b013e318288ab02
10.1016/j.ijrobp.2015.10.004
10.1200/jco.19.02503
10.1186/1471-2407-10-606
10.1200/jco.2017.35.15_suppl.4118
10.1093/jrr/rrw117
10.1002/cncr.32502
10.1016/j.ijrobp.2020.07.903
10.1016/j.ijrobp.2016.12.028
10.4143/crt.2017.070
10.1007/s00066-015-0825-3
10.1016/j.radonc.2020.09.018
10.1097/jto.0b013e3181560a68
10.1007/s00535-011-0398-6
10.1016/s1470-2045(18)30931-8
10.3857/roj.2020.00703
10.1016/s0167-8140(02)00367-5
10.14338/ijpt.14-00006.1
10.1186/1471-2407-10-607
10.1002/cncr.28387
10.1001/jamaoncol.2019.0892
10.1080/0284186x.2020.1769184
10.1002/cncr.29195
10.1259/bjr.20130512
10.1016/j.ijrobp.2015.12.003
10.1200/jco.2002.10.050
10.3390/cancers13020176
10.1007/bf03038890
10.1055/s-0036-1579545
10.1016/j.radonc.2016.04.025
10.1002/cncr.30816
10.1016/j.jtho.2016.12.012
10.1016/j.ijrobp.2004.01.032
10.1016/j.clon.2017.11.002
10.1016/j.ijrobp.2019.01.076
10.1007/s11060-020-03464-1
10.18632/oncotarget.27028
10.1167/iovs.06-0659
10.21037/tlcr.2019.07.08
10.3109/0284186x.2012.762997
10.1016/j.radonc.2019.03.012
10.1038/nrclinonc.2017.30
10.1177/1533033818783879
10.1053/j.seminoncol.2019.07.005
10.1001/jamaoncol.2018.0329
10.1186/s13014-019-1210-7
10.3748/wjg.v24.i28.3090
10.1016/j.ijrobp.2012.08.026
10.1038/bjc.2014.191
10.1093/jjco/hyw102
10.3748/wjg.v26.i4.393
10.1016/j.ijrobp.2016.01.057
10.3390/cancers12092395
10.1056/nejmoa010580
10.14316/pmp.2020.31.3.71
10.1016/j.adro.2018.04.003
10.1016/j.ijrobp.2017.11.010
10.1245/s10434-014-4219-z
10.1016/j.radonc.2018.10.009
10.1016/j.ijrobp.2016.02.027
10.3390/cancers10030066
10.1111/j.1442-2042.2012.02961.x
10.1016/j.ijrobp.2010.03.015
10.1016/j.jhep.2020.09.026
10.1016/j.ijrobp.2017.06.2450
10.1016/s1470-2045(14)70268-2
10.3857/roj.2018.00164
10.1093/jrr/rrx037
10.1259/bjr.20190873
10.1007/s00535-013-0857-3
10.21873/anticanres.13963
10.1016/j.ijrobp.2016.02.012
10.1200/jco.2017.74.0720
10.1002/cncr.29882
10.1038/s41416-018-0324-2
10.1002/cam4.1159
10.21037/jgo.2019.03.02
10.1016/j.radonc.2018.10.007
10.1016/s1470-2045(15)00167-9
10.1016/j.radonc.2010.05.019
10.1016/j.ijrobp.2007.09.056
10.1016/j.radonc.2018.02.003
10.1016/j.radonc.2006.08.015
10.1002/cncr.31958
10.1016/j.ijrobp.2015.12.362
10.1016/j.ijrobp.2006.10.006
10.1016/j.ijrobp.2016.10.030
10.1016/j.ijrobp.2018.04.057
10.3389/fonc.2020.00542
10.1016/j.ijrobp.2009.02.030
10.1111/iju.14041
10.1016/j.ijrobp.2018.05.074
10.1016/j.radonc.2011.12.029
10.3390/cancers12010163
10.1002/cncr.27723
10.1259/bjr.20190516
10.1200/jco.2015.64.2710
10.1016/j.radonc.2017.11.028
10.1186/s13014-019-1221-4
ContentType Journal Article
Copyright Copyright © 2021 by the Korean Cancer Association 2021
Copyright_xml – notice: Copyright © 2021 by the Korean Cancer Association 2021
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ACYCR
DOI 10.4143/crt.2021.299
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
Korean Citation Index
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE

MEDLINE - Academic
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2005-9256
EndPage 634
ExternalDocumentID oai_kci_go_kr_ARTI_9843749
PMC8291184
34176253
10_4143_crt_2021_299
Genre Journal Article
Comparative Study
Review
GrantInformation_xml – fundername: Ministry of Science and ICT
– fundername: National Research Foundation of Korea
  grantid: 2019M2A2B4095126
– fundername: National Research Foundation of Korea
  grantid: 2019R1F1A1040583
GroupedDBID ---
29B
5-W
53G
8JR
9ZL
AAYXX
ABDBF
ACUHS
ACYCR
ADBBV
AENEX
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CITATION
DIK
E3Z
EBD
EF.
F5P
HYE
OK1
RPM
TR2
C1A
CGR
CUY
CVF
ECM
EIF
M~E
NPM
7X8
5PM
08R
ID FETCH-LOGICAL-c348t-3e7ca6bd268dff5d4c0ae3a0aae7a695216926956127cf473e7465c371ddcd073
ISSN 1598-2998
2005-9256
IngestDate Tue Nov 21 21:41:08 EST 2023
Thu Aug 21 14:32:11 EDT 2025
Fri Jul 11 03:48:13 EDT 2025
Thu Jan 02 22:34:03 EST 2025
Tue Jul 01 03:18:51 EDT 2025
Thu Apr 24 23:01:20 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords Carbon-ion radiotherapy
Charged-particle therapy
Proton beam therapy
Language English
License This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c348t-3e7ca6bd268dff5d4c0ae3a0aae7a695216926956127cf473e7465c371ddcd073
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-Review-3
content type line 23
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC8291184
PMID 34176253
PQID 2545991689
PQPubID 23479
PageCount 14
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_9843749
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8291184
proquest_miscellaneous_2545991689
pubmed_primary_34176253
crossref_primary_10_4143_crt_2021_299
crossref_citationtrail_10_4143_crt_2021_299
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-07-01
PublicationDateYYYYMMDD 2021-07-01
PublicationDate_xml – month: 07
  year: 2021
  text: 2021-07-01
  day: 01
PublicationDecade 2020
PublicationPlace Korea (South)
PublicationPlace_xml – name: Korea (South)
PublicationTitle Cancer research and treatment
PublicationTitleAlternate Cancer Res Treat
PublicationYear 2021
Publisher Korean Cancer Association
대한암학회
Publisher_xml – name: Korean Cancer Association
– name: 대한암학회
References ref57
ref56
ref59
ref58
ref52
ref55
ref51
ref50
ref46
ref45
ref47
ref42
ref41
ref44
ref43
Nakajima (ref53) 2017
ref49
Shiba (ref95) 2017
ref8
(ref9) 2009
ref4
ref3
ref6
ref5
ref100
ref101
ref40
ref35
ref34
ref37
ref36
ref31
ref148
ref30
ref149
ref33
ref146
ref32
ref147
Saitoh (ref69) 2018
ref39
ref38
ref155
ref156
ref153
ref154
ref151
ref152
ref150
ref24
ref23
ref26
ref25
ref20
Spychalski (ref79) 2019
ref22
ref21
Chang (ref48) 2016
ref28
ref29
ref13
ref12
ref15
ref128
ref14
ref129
ref97
ref126
ref96
ref11
ref99
ref124
ref10
ref98
ref125
ref17
ref16
ref19
ref18
ref93
ref133
ref92
ref134
ref131
ref94
ref132
ref130
ref91
ref90
ref89
ref139
ref86
ref137
ref85
ref138
ref88
ref135
ref87
ref136
(ref7) 2021
Suefuji (ref27) 2018
ref82
ref144
ref81
ref145
ref84
ref142
ref83
ref143
ref140
ref141
ref80
ref108
ref78
ref109
ref106
Karube (ref54) 2016
ref107
ref75
ref104
ref74
ref105
ref77
ref102
ref76
ref103
ref2
ref1
ref71
ref111
ref70
ref112
ref73
ref72
ref110
ref68
ref119
ref67
ref117
ref118
ref64
ref115
ref63
ref116
ref66
ref113
ref65
ref114
Hong (ref127) 2014
ref60
ref122
ref123
ref62
ref120
ref61
ref121
References_xml – ident: ref12
  doi: 10.1016/j.radonc.2014.08.017
– ident: ref129
  doi: 10.1002/cam4.1350
– ident: ref89
  doi: 10.1007/s00066-009-2020-x
– ident: ref51
  doi: 10.1186/s13014-016-0637-3
– ident: ref102
  doi: 10.1186/1748-717x-9-26
– ident: ref123
  doi: 10.1200/jco.19.02274
– ident: ref11
  doi: 10.37765/ajmc.2020.42398
– ident: ref84
  doi: 10.1111/hepr.12874
– ident: ref33
  doi: 10.1080/02841860500326257
– ident: ref19
  doi: 10.1016/j.ijrobp.2006.09.022
– ident: ref50
  doi: 10.1016/j.ijrobp.2013.05.002
– ident: ref128
  doi: 10.1186/s12885-019-6108-0
– ident: ref64
  doi: 10.1016/j.ijrobp.2015.11.004
– ident: ref90
  doi: 10.1016/j.radonc.2016.12.014
– ident: ref3
  doi: 10.1159/000486997
– ident: ref130
  doi: 10.1016/j.ijrobp.2013.11.007
– ident: ref55
  doi: 10.1016/j.radonc.2017.05.007
– ident: ref62
  doi: 10.1016/s1470-2045(14)71207-0
– ident: ref149
  doi: 10.21873/invivo.11944
– ident: ref101
  doi: 10.1016/j.adro.2019.09.007
– ident: ref73
  doi: 10.3857/roj.2019.00633
– ident: ref121
  doi: 10.1259/bjr.20160790
– ident: ref20
  doi: 10.1001/archotol.132.11.1242
– ident: ref135
  doi: 10.1016/j.radonc.2016.10.009
– ident: ref32
  doi: 10.1016/j.radonc.2017.12.017
– start-page: 127
  volume-title: Patient specific outcomes of charged particle therapy for hepatocellular carcinoma: a systematic review and quantitative analysis
  year: 2019
  ident: ref79
– ident: ref28
  doi: 10.1002/cam4.1830
– ident: ref46
  doi: 10.1016/j.ijrobp.2008.12.019
– ident: ref1
  doi: 10.4143/crt.2017.096
– ident: ref45
  doi: 10.1002/cam4.1679
– ident: ref132
  doi: 10.1016/j.ijrobp.2016.02.038
– ident: ref151
  doi: 10.1056/nejmoa1209825
– ident: ref2
  doi: 10.3390/cancers9060066
– start-page: 830
  volume-title: A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma
  year: 2014
  ident: ref127
– ident: ref100
  doi: 10.1186/s13014-019-1347-4
– ident: ref22
  doi: 10.1016/j.radonc.2015.05.010
– ident: ref152
  doi: 10.1016/j.ijrobp.2016.02.031
– ident: ref65
  doi: 10.1093/jrr/rru034
– ident: ref144
  doi: 10.1002/jso.22127
– ident: ref150
  doi: 10.1186/s13014-020-01653-w
– ident: ref67
  doi: 10.1111/cas.13890
– start-page: 542
  volume-title: Single-fraction carbon-ion radiation therapy for patients 80 years of age and older with stage I non-small cell lung cancer
  year: 2016
  ident: ref54
– ident: ref61
  doi: 10.3390/cancers13010112
– ident: ref14
  doi: 10.1016/j.radonc.2019.04.027
– ident: ref117
  doi: 10.1016/j.radonc.2018.08.026
– ident: ref6
  doi: 10.1259/bjr.20200183
– ident: ref76
  doi: 10.1158/1078-0432.ccr-04-1350
– ident: ref138
  doi: 10.1016/j.ijrobp.2012.01.072
– ident: ref91
  doi: 10.1007/s00066-014-0604-6
– ident: ref36
  doi: 10.1097/brs.0b013e318296e7d7
– ident: ref49
  doi: 10.1097/jto.0b013e318288ab02
– ident: ref156
  doi: 10.1016/j.ijrobp.2015.10.004
– ident: ref142
  doi: 10.1200/jco.19.02503
– ident: ref40
  doi: 10.1186/1471-2407-10-606
– ident: ref126
  doi: 10.1200/jco.2017.35.15_suppl.4118
– ident: ref24
  doi: 10.1093/jrr/rrw117
– ident: ref80
  doi: 10.1002/cncr.32502
– ident: ref125
  doi: 10.1016/j.ijrobp.2020.07.903
– ident: ref25
  doi: 10.1016/j.ijrobp.2016.12.028
– ident: ref17
  doi: 10.4143/crt.2017.070
– ident: ref41
  doi: 10.1007/s00066-015-0825-3
– ident: ref42
  doi: 10.1016/j.radonc.2020.09.018
– ident: ref58
  doi: 10.1097/jto.0b013e3181560a68
– ident: ref92
  doi: 10.1007/s00535-011-0398-6
– ident: ref140
  doi: 10.1016/s1470-2045(18)30931-8
– ident: ref10
  doi: 10.3857/roj.2020.00703
– ident: ref57
  doi: 10.1016/s0167-8140(02)00367-5
– ident: ref112
  doi: 10.14338/ijpt.14-00006.1
– start-page: 505
  volume-title: Consensus Statement on Proton Therapy in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer
  year: 2016
  ident: ref48
– ident: ref39
  doi: 10.1186/1471-2407-10-607
– ident: ref15
  doi: 10.1002/cncr.28387
– ident: ref124
  doi: 10.1001/jamaoncol.2019.0892
– ident: ref146
  doi: 10.1080/0284186x.2020.1769184
– start-page: 144
  volume-title: Carbon-ion radiotherapy for non-small cell lung cancer with interstitial lung disease: a retrospective analysis
  year: 2017
  ident: ref53
– ident: ref70
  doi: 10.1002/cncr.29195
– ident: ref43
  doi: 10.1259/bjr.20130512
– ident: ref106
  doi: 10.1016/j.ijrobp.2015.12.003
– ident: ref47
  doi: 10.1200/jco.2002.10.050
– ident: ref56
  doi: 10.3390/cancers13020176
– ident: ref31
  doi: 10.1007/bf03038890
– ident: ref21
  doi: 10.1055/s-0036-1579545
– ident: ref63
  doi: 10.1016/j.radonc.2016.04.025
– ident: ref97
  doi: 10.1002/cncr.30816
– ident: ref60
  doi: 10.1016/j.jtho.2016.12.012
– ident: ref94
  doi: 10.1016/j.ijrobp.2004.01.032
– ident: ref154
  doi: 10.1016/j.clon.2017.11.002
– ident: ref82
  doi: 10.1016/j.ijrobp.2019.01.076
– ident: ref38
  doi: 10.1007/s11060-020-03464-1
– ident: ref104
  doi: 10.18632/oncotarget.27028
– ident: ref16
  doi: 10.1167/iovs.06-0659
– ident: ref72
  doi: 10.21037/tlcr.2019.07.08
– ident: ref107
  doi: 10.3109/0284186x.2012.762997
– ident: ref109
  doi: 10.1016/j.radonc.2019.03.012
– ident: ref4
  doi: 10.1038/nrclinonc.2017.30
– ident: ref111
  doi: 10.1177/1533033818783879
– ident: ref5
  doi: 10.1053/j.seminoncol.2019.07.005
– ident: ref122
  doi: 10.1001/jamaoncol.2018.0329
– ident: ref133
  doi: 10.1186/s13014-019-1210-7
– ident: ref81
  doi: 10.3748/wjg.v24.i28.3090
– start-page: 885
  volume-title: A phase I study of hypofractionated carbon-ion radiotherapy for stage III non-small cell lung cancer
  year: 2018
  ident: ref69
– ident: ref18
  doi: 10.1016/j.ijrobp.2012.08.026
– ident: ref137
  doi: 10.1038/bjc.2014.191
– ident: ref77
  doi: 10.1093/jjco/hyw102
– ident: ref75
  doi: 10.3748/wjg.v26.i4.393
– ident: ref35
  doi: 10.1016/j.ijrobp.2016.01.057
– ident: ref88
  doi: 10.3390/cancers12092395
– ident: ref145
  doi: 10.1056/nejmoa010580
– ident: ref74
  doi: 10.14316/pmp.2020.31.3.71
– ident: ref113
  doi: 10.1016/j.adro.2018.04.003
– ident: ref23
  doi: 10.1016/j.ijrobp.2017.11.010
– year: 2021
  ident: ref7
– ident: ref148
  doi: 10.1245/s10434-014-4219-z
– ident: ref85
  doi: 10.1016/j.radonc.2018.10.009
– ident: ref99
  doi: 10.1016/j.ijrobp.2016.02.027
– ident: ref78
  doi: 10.3390/cancers10030066
– ident: ref134
  doi: 10.1111/j.1442-2042.2012.02961.x
– ident: ref93
  doi: 10.1016/j.ijrobp.2010.03.015
– ident: ref98
  doi: 10.1016/j.jhep.2020.09.026
– ident: ref143
  doi: 10.1016/j.ijrobp.2017.06.2450
– ident: ref26
  doi: 10.1016/s1470-2045(14)70268-2
– ident: ref34
  doi: 10.3857/roj.2018.00164
– ident: ref68
  doi: 10.1093/jrr/rrx037
– ident: ref8
  doi: 10.1259/bjr.20190873
– ident: ref110
  doi: 10.1007/s00535-013-0857-3
– ident: ref66
  doi: 10.21873/anticanres.13963
– ident: ref44
  doi: 10.1016/j.ijrobp.2016.02.012
– ident: ref71
  doi: 10.1200/jco.2017.74.0720
– ident: ref153
  doi: 10.1002/cncr.29882
– ident: ref155
  doi: 10.1038/s41416-018-0324-2
– start-page: 1665
  volume-title: A retrospective multicenter study of carbon ion radiotherapy for locally advanced olfactory neuroblastomas
  year: 2018
  ident: ref27
– ident: ref131
  doi: 10.1002/cam4.1159
– ident: ref114
  doi: 10.21037/jgo.2019.03.02
– ident: ref147
  doi: 10.1016/j.radonc.2018.10.007
– start-page: 721
  volume-title: Carbon ion radiotherapy for 80 years or older patients with hepatocellular carcinoma
  year: 2017
  ident: ref95
– ident: ref13
  doi: 10.1016/s1470-2045(15)00167-9
– ident: ref87
  doi: 10.1016/j.radonc.2010.05.019
– ident: ref86
  doi: 10.1016/j.ijrobp.2007.09.056
– ident: ref120
  doi: 10.1016/j.radonc.2018.02.003
– ident: ref136
  doi: 10.1016/j.radonc.2006.08.015
– ident: ref37
  doi: 10.1002/cncr.31958
– ident: ref118
  doi: 10.1016/j.ijrobp.2015.12.362
– ident: ref59
  doi: 10.1016/j.ijrobp.2006.10.006
– ident: ref105
  doi: 10.1016/j.ijrobp.2016.10.030
– ident: ref116
  doi: 10.1016/j.ijrobp.2018.04.057
– ident: ref96
  doi: 10.3389/fonc.2020.00542
– year: 2009
  ident: ref9
– ident: ref83
  doi: 10.1016/j.ijrobp.2009.02.030
– ident: ref139
  doi: 10.1111/iju.14041
– ident: ref29
  doi: 10.1016/j.ijrobp.2018.05.074
– ident: ref108
  doi: 10.1016/j.radonc.2011.12.029
– ident: ref115
  doi: 10.3390/cancers12010163
– ident: ref119
  doi: 10.1002/cncr.27723
– ident: ref30
  doi: 10.1259/bjr.20190516
– ident: ref103
  doi: 10.1200/jco.2015.64.2710
– ident: ref141
  doi: 10.1016/j.radonc.2017.11.028
– ident: ref52
  doi: 10.1186/s13014-019-1221-4
SSID ssj0064371
Score 2.251216
SecondaryResourceType review_article
Snippet Charged-particle therapy (CPT) such as proton beam therapy (PBT) and carbon-ion radiotherapy (CIRT) exhibit substantial physical and biological advantages...
SourceID nrf
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 621
SubjectTerms Cost-Benefit Analysis
Heavy Ion Radiotherapy - adverse effects
Heavy Ion Radiotherapy - economics
Heavy Ion Radiotherapy - methods
Humans
Incidence
Neoplasms - radiotherapy
Organs at Risk - radiation effects
Patient Selection
Photons - adverse effects
Radiation Injuries - epidemiology
Radiation Injuries - etiology
Special
Treatment Outcome
의학일반
Title Who Will Benefit from Charged-Particle Therapy?
URI https://www.ncbi.nlm.nih.gov/pubmed/34176253
https://www.proquest.com/docview/2545991689
https://pubmed.ncbi.nlm.nih.gov/PMC8291184
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002738402
Volume 53
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Cancer Research and Treatment, 2021, 53(3), , pp.621-634
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Nb9MwFLfYJiEuiPG1bgwFBKcqm-u4TnJC62AMEIjDJnazHNvpqqFkypID_PW8FztZGxVpcEmqxI4V_17fR_zez4S84dRSo1MRGprTkOdahCpRPLQZzSYmMSZRbYLsN3F6zj9fTC-6DcZ9dUmdHejfa-tK_gdVuAa4YpXsPyDbPxQuwG_AF46AMBzvhPGPy7KlVRjPQGPli9oVi-AK-tya8LvvgVkVyBwwyOE7RryrsWf7cQVufdr57dJ8Ky9ffjVI3N30KrxpTVZZzMOPcGv50wGb9GmmvbZLsQTDbQN9YNtrLTVpyhzbd6ciHZ-vF4VoSd8JV97sTadw3yWHWpmDTwZTqSvMXWUQlLstkVbJrwdGqU8VhCAF-0voLbG3hN4bZIvFMa7Kbx3N3s9OOtOLi5COINe_l6t0wP6Hy6Ov-CAbRZWvCy-GWbJLbsfZI_LQxwvBkYNym9yzxWNy_6vPiHhCDkEGApSBwMtAgDIQDGUg8DLw7ik5P_lwdnwa-k0wQh3xpA4jG2slMsNEYvJ8arimykaKKmVjJVLwvkTKBJYns1jnPIb2XEw1TIQx2oACf0Y2i7KwOySYqFiYVEzgeRAXa6Mo58wYbhQECTlVIzLupkVqzxCPG5X8lOtAGJG3fetrx4zyl3avYYbllV5IpDLH87yUV5WEgO2TTBPAjEOjVx0AEvQbLlqpwpbNjWTg4mMMk0Cb5w6QfjjwwMCWT6MRiVeg6hvggKt3isVly6GeMLDyCd-940vskQe3f6AXZLOuGrsP3midvfQy-AfWBoiM
linkProvider EBSCOhost
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Who+Will+Benefit+from+Charged-Particle+Therapy%3F&rft.jtitle=Cancer+research+and+treatment&rft.au=Kim%2C+Kyung+Su&rft.au=Wu%2C+Hong-Gyun&rft.date=2021-07-01&rft.issn=1598-2998&rft.eissn=2005-9256&rft.volume=53&rft.issue=3&rft.spage=621&rft.epage=634&rft_id=info:doi/10.4143%2Fcrt.2021.299&rft.externalDBID=n%2Fa&rft.externalDocID=10_4143_crt_2021_299
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1598-2998&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1598-2998&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1598-2998&client=summon